Comprehensive analysis of STAT family members as prognostic markers in human breast cancer

Breast cancer has the highest morbidity and mortality among cancers in women owing to its malignancy, and its incidence increases with age. However, the specific mechanisms underlying breast cancer recurrence and metastasis remain poorly understood. Numerous tumors have shown extensive dependence on janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling. However, the STAT family has not yet been studied systematically in breast cancer. In this study, we investigated the expression differences, prognostic values, molecular functions, and immune infiltration of STAT members in breast cancer. For these analyses, we used The Cancer Genome Atlas (TCGA), cBioPortal, Kaplan-Meier plotter, and the TIMER databases. Significant changes were observed in the STAT expression in breast cancer, and higher expression levels of STAT1/3/4/5A/5B/6 were associated with a longer overall survival in breast cancer. Moreover, significant differences in STAT3, STAT5A, and STAT6 expression were observed at different tumor stages. Members of the STAT family and the associated genes were found to be involved in the regulation of various biological functions, such as “defense response to virus”, “innate immune response”, and “protein binding” in breast cancer. The expression levels of the STAT family members were positively associated with the infiltration of B cells, CD4+T cells, CD8+T cells, macrophages, dendritic cells, and neutrophils in breast cancer. Our results indicate that the expression of the members of the STAT family may be correlated with breast cancer progression and prognosis. Therefore, the STAT family can be used as a prognostic biomarker for confirming disease prognosis and immune infiltration levels in breast cancer.

Bioinformatics analysis; STAT family; Breast cancer; Tumor microenvironment; Prognosis

[1] Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. International Immunopharmacology. 2020; 84:106535.

[2] Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, et al. Breast cancer diagnosis: imaging techniques and biochemical markers. Journal of Cellular Physiology. 2018; 233: 5200–5213.

[3] Britt KL, Cuzick J, Phillips K. Key steps for effective breast cancer prevention. Nature Reviews Cancer. 2020; 20: 417–436.

[4] Semiglazov V, Tseluiko A, Kudaybergenova A, Artemyeva A, Krivorotko P, Donskih R. Immunology and immunotherapy in breast cancer. Cancer Biology & Medicine. 2022; 19: 609–618.

[5] Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. European Journal of Pharmacology. 2018; 834: 188–196.

[6] Kumar U, Ardasheva A, Mahmud Z, Coombes RC, Yague E. FOXA1 is a determinant of drug resistance in breast cancer cells. Breast Cancer Research and Treatment. 2021; 186: 317–326.

[7] Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Medicinal Chemistry. 2015; 7: 1511–1519.

[8] Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology. 2020; 80: 106210.

[9] Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy. 2021; 6: 402.

[10] Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers. 2019; 11: 2002.

[11] Nobel YR, Stier K, Krishnareddy S. STAT signaling in the intestine. Signal Transduction in Cancer and Immunity. 2021; 296: 1–20.

[12] Dodington DW, Desai HR, Woo M. JAK/STAT—emerging players in metabolism. Trends in Endocrinology & Metabolism. 2018; 29: 55–65.

[13] Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein science: a publication of the Protein Society. 2018; 27: 1984–2009.

[14] Tang S, Yuan X, Song J, Chen Y, Tan X, Li Q. Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer. Oncology Letters. 2019; 17: 159–164.

[15] Wang L, Xu D, Cai L, Dai J, Li Y, Xu H. Expression and survival analysis of the STAT gene family in diffuse gliomas using integrated bioinformatics. Current Research in Translational Medicine. 2021; 69: 103274.

[16] Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, et al. The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology. 2020; 60: 41–56.

[17] Tanaka A, Zhou Y, Ogawa M, Shia J, Klimstra DS, Wang JY, et al. STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability. PLoS One. 2020; 15: e0229252.

[18] Walter KR, Balko JM, Hagan CR. Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer. OncoImmunology. 2020; 9: 1758547.

[19] Fan X, Fu H, Xie N, Guo H, Fu T, Shan Y. Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Aging. 2021; 13: 22830–22842.

[20] Nishi M, Batsaikhan BE, Yoshikawa K, Higashijima J, Tokunaga T, Takasu C, et al. High STAT4 expression indicates better disease-free survival in patients with gastric cancer. Anticancer Research. 2017; 37: 6723–6729.

[21] Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, et al. STAT3 and STAT5a are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget. 2017; 8: 85997–86010.

[22] Sumiyoshi H, Matsushita A, Nakamura Y, Matsuda Y, Ishiwata T, Naito Z, et al. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Oncology Reports. 2016; 35: 3216–3226.

[23] Wang L, Yu S, Yin Y, Hao Y. STAT6 correlates with response to immune checkpoint blockade therapy and predicts worse survival in thyroid cancer. Biomarkers in Medicine. 2020; 14: 955–967.

[24] Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9: 166–180.

[25] Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. Journal of Medical Internet Research. 2021; 23: e27633.

[26] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012; 2: 401–404.

[27] Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAn-alyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Research. 2019; 47: W234–W241.

[28] Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018; 10: 277–288.

[29] Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research. 2020; 48: W509–W514.

[30] Liu C, Hu F, Xia M, Han L, Zhang Q, Guo A. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018; 34: 3771–3772.

[31] Győrffy B, Bottai G, Fleischer T, Munkácsy G, Budczies J, Paladini L, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer. 2016; 138: 87–97.

[32] Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Frontiers in Immunology. 2020; 11: 369.

[33] Petitprez F, Meylan M, de Reynies A, Sautes-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Frontiers in Immunology. 2020; 11: 784.

[34] Yang Y, Liu P, Li D, Yang Q, Li B, Jiang X. Stat-3 signaling promotes cell proliferation and metastasis of gastric cancer through PDCD4 downregulation. The Kaohsiung Journal of Medical Sciences. 2020; 36: 244–249.

[35] O’Reilly LA, Putoczki TL, Mielke LA, Low JT, Lin A, Preaudet A, et al. Loss of NF-κB1 causes gastric cancer with aberrant inflammation and expression of immune checkpoint regulators in a STAT-1-dependent manner. Immunity. 2018; 48: 570–583.e8.

[36] Nguyen TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T, et al. Mutations in the IFNgamma-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment. Clinical Cancer Research. 2021; 27: 3432–3442.

[37] Singh R, Dagar P, Pal S, Basu B, Shankar BS. Significant alterations of the novel 15 gene signature identified from macrophage-tumor interactions in breast cancer. Biochimica et Biophysica Acta-General Subjects. 2018; 1862: 669–683.

[38] Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, et al. PhosphoSTAT1 expression as a potential biomarker for an-tiPD1/antiPDL1 immunotherapy for breast cancer. International Journal of Oncology. 2019; 54: 2030–2038.

[39] Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Research. 2012; 14: R16.

[40] Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. Journal of Proteomics. 2012; 75: 3031–3040.

[41] Furth PA. STAT signaling in different breast cancer sub-types. Molecular and Cellular Endocrinology. 2014; 382: 612–615.

[42] Wang S, Yu L, Shi W, Li X, Yu L. Prognostic roles of signal transducers and activators of transcription family in human breast cancer. Bioscience Reports. 2018; 38: BSR20171175.

[43] Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2005; 24: 746–760.

[44] Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: role of tumor‐associated macrophages in the tumor microenvironment. Cancer Medicine. 2019; 8: 4709–4721.

[45] Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 2017; 8: 607.

[46] Lechner A, Schlößer HA, Thelen M, Wennhold K, Rothschild SI, Gilles R, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. OncoImmunology. 2019; 8: 1535293.

[47] Li W, Zeng J, Luo B, Mao Y, Liang Y, Zhao W, et al. High expression of activated CD4(+) memory T cells and CD8(+) T cells and low expression of M0 macrophage are associated with better clinical prognosis in bladder cancer patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020; 36: 97–103.(In Chinese)

[48] Sanchez-Correa B, Lopez-Sejas N, Duran E, Labella F, Alonso C, Solana R, et al. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. Cancer Immunology, Immunotherapy. 2019; 68: 861–870.

[49] Martin-Lluesma S, Graciotti M, Grimm AJ, Boudousquié C, Chiang CL, Kandalaft LE. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? Current Opinion in Biotechnology. 2020; 65: 190–196.

[50] Berg J, Lindberg M, Bengtson M, Brustugun OT, Helland A. The neutrophil and platelet to lymphocyte ratios and glasgow prognostic score as a predictor for relapse after stereotactic radiation for lung cancer. Journal of Thoracic Oncology. 2019; 14: S1102–S1102.

[51] Cao Y, Chen C, Tao Y, Lin W, Wang P. Immunotherapy for triple-negative breast cancer. Pharmaceutics. 2021; 13: 2003.

[52] Skala MC, Ayuso JM, Burkard ME, Deming DA. Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays. Current Opinion in Biomedical Engineering. 2022; 21: 100348.

[53] Wu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, et al. Endocrine therapy for hormone receptor-positive advanced breast cancer: a nation-wide multicenter epidemiological study in China. Frontiers in Oncology. 2020; 10: 599604.

[54] Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W. The Role of miRNAs in the resistance of anthracyclines in breast cancer: a systematic review. Frontiers in Oncology. 2022; 12: 899145.

[55] Ning S, Li H, Qiao K, Wang Q, Shen M, Kang Y, et al. Identification of long-term survival-associated gene in breast cancer. Aging. 2020; 12: 20332–20349.